Last reviewed · How we verify

NCT04032808

Evaluation of the Performance of Self-monitoring Optimized by Therapeutic Education in the Recurrence of Wet Age-related Macular Degeneration (AMD)

Status unknown Last updated 9 February 2021
What this trial tests

trial in Age-related Macular Degeneration in 70 participants. Status unknown.

Timeline
10 July 2019
Primary endpoint
10 July 2021
10 July 2021

Quick facts

Lead sponsorClinique Beau Soleil
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment70
Start date10 July 2019
Primary completion10 July 2021
Estimated completion10 July 2021
Sites1 location across France

Conditions studied

Sponsor

Clinique Beau Soleil

Who can join

50 and older, any sex, with Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Monocentric and prospective study, evaluating the benefit of self-monitoring optimized by therapeutic education either by the environmental Amsler or the Amsler grid according to the patient's choice and to determine the patient's ability to determine the reality itself recidivism and therefore the need for treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Age-related Macular Degeneration

Currently open trials in the same condition.

Other Clinique Beau Soleil trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04032808.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing